Emyria posts A$7m loss but insists 2023 will be ‘momentous’ by Steve Jones August 30, 2022April 29, 2024 Emyria posted a 5% lift in revenue in FY22 but losses deepened amid a sharp rise […]
Emyria losses deepen as drug development takes centre stage by Steve Jones March 1, 2022April 29, 2024
TGA releases findings on MDMA and psilocybin as mental health treatments by Martin Lane October 5, 2021April 26, 2024
Company news: Emyria; Medibis; Incannex; Eqalis; Greenfern; Creso Pharma; Highlands Investments by Martin Lane August 12, 2021April 26, 2024
